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Background:  Catheter ablation of atrial fibrillation (AF) has been increasingly used in experienced electrophysiology centers. A novel ablation 
system delivering duty-cycled phased radiofrequency energy via an over-the-wire multipolar circular ablation catheter (PVAC™, Medtronic) to perform 
linear continuous ablation has been tested for isolation of pulmonary veins (PVs).
Methods:  224 patients underwent PV isolation using the novel ablation system and the PVAC catheter. In addition, in patients with persistent 
AF (N=66) catheters specifically designed for ablation of complex fractionated electrograms at the septum (MASC™) and within the left atrium 
(MAAC™) have been applied. Follow-up consisted of 7-day-holter EKG recordings every 3 months after the procedure.
Results: During the ablation procedure 852 out of 856 (99%) were effectively isolated during a mean procedure duration of 108(±29)minutes, 
radiation duration of 22(±9)minutes and ablation duration of 27:37 (±8:36)minutes. In patients with persistent AF PV isolation alone was performed 
in 26, additional ablation of the septum in 20 and/or ablations with the MAAC in 20.
During a median follow-up of 9months 67% of paroxysmal patients and 48% of persistent AF patients had no AF documented after a single ablation 
procedure. 14 patients underwent redo-procedures. 7 (3%) patients had procedure- but not device-related complications.
Comparing the initial 30 paroxysmal AF patients undergoing ablation to the last 30 patients with completed follow-up there is a significant 
reduction in procedure duration (112 vs. 97min) and radiation exposure (22min vs. 18min). 53% of the first and 80% of the last patients had no AF 
documented during follow-up.
Conclusions:  Using a novel duty-cycled phased radiofrequency ablation system is effective and safe in treating AF patients. PV isolation can 
acutely be achieved in 99% of targeted veins. Mid-term success using a stringent criterion of no AF is 67% for paroxysmal and 48% for persistent AF 
patients using mainly PV-isolation alone. There is a learning curve leading to shorter procedures and a trend towards higher success rates.
